Bioprinting company CELLINK acquired the life science company cytena GmbH – a spin-off of the Institute for Microsystems Technology (IMTEK) at the University of Freiburg.
The acquisition with a value of €30.25M aims to lift synergies in marketing, sales and R&D between the member companies.
The purchase will be paid partly in cash and partly in CELLINK shares. Cytena is well known in the biomedical field for its patented single-cell printer technology, which allows the isolation and dispensing of single cells for the production of clonal cell lines for manufacturing biologicals. Cytena’s turnaround is estimated to be €4.5 million in 2019 with an EBITDA-margin of about 40%.
The strategic acquisition aims to offer solutions for both academic and pharmaceutical customers worldwide.